What UK Peptides Lab is

What this desk is

UK Peptides Lab is an independent literature digest. It does not operate a physical laboratory, run assays, or sell products. It does not employ researchers, conduct original experiments, or hold any regulatory status. What it does is collect, organise, and summarise the published peer-reviewed research literature on specific research peptides — in this version of the desk, the three compounds studied in immune and tissue-repair research: Thymosin Alpha-1, KPV, and BPC-157.

The name Lab is editorial framing: a reading desk that treats the published literature as its source material and applies the same rigour to summarising it that a careful laboratory technician applies to running an experiment. The framing is about precision and method, not about white coats or bench equipment.

This resource is intended for readers who want to understand what the peer-reviewed science actually says about these compounds — without the promotional framing of a vendor, the clinical authority of a physician, or the vagueness of a wellness blog. It is a middle path: structured, cited, and honest about the limits of the evidence.

Editorial method

Every factual claim on this desk is attributed to a specific published source and cited by reference number. The full reference list — with authors, journals, years, DOIs, and PubMed IDs where available — is available on the References page.

When selecting sources, the desk prioritises peer-reviewed primary literature (original research articles) and systematic reviews over secondary or non-peer-reviewed sources. Where the evidence base is predominantly preclinical (cell or animal studies), that is stated plainly — not in a footnote, but in the main text. Where trials have returned null results, those results are reported with the same prominence as positive findings. The 2025 TESTS phase-3 sepsis trial for Thymosin Alpha-1, which returned a hazard ratio of 0.99 and a null P-value, receives direct treatment in the Thymosin Alpha-1 page and in the FAQ — not relegation to a parenthetical.

Terminological precision is a particular concern on this desk. Research peptides accumulate confusing synonyms, naming overlaps, and outright errors in secondary sources. This desk is explicit about what each compound is and, equally, what it is not: Thymosin Alpha-1 is not thymulin and not TB-500/thymosin-β4; BPC-157 is not a growth hormone; KPV's mechanism is MC1R-independent.

No human dose is listed anywhere on this desk. References to dosing in the clinical literature describe how study protocols were designed; they are not instructions.

Independence and disclaimer

UK Peptides Lab has no commercial relationship with any peptide supplier, pharmaceutical company, compounding pharmacy, or clinical service provider. It does not receive referral fees, affiliate revenue, or sponsored content payments. It does not link outward to vendors.

The content on this desk is educational commentary on publicly available research. It is not medical advice, a clinical recommendation, or a substitute for consultation with a qualified healthcare professional. None of the compounds described here are approved medicines in the United States. None of the information here is intended to diagnose, treat, cure, or prevent any disease or condition.

Readers are encouraged to verify citations at source — every reference includes a PubMed URL or DOI link — and to consult the primary literature directly. This desk makes its reasoning transparent precisely so that readers do not have to take its summaries on trust; they can follow the reference chain and evaluate the evidence themselves.